Ghofrani, Hossein-Ardeschir, Gruenig, Ekkehard, Jansa, Pavel ORCID: 0000-0002-3711-7064, Langleben, David, Rosenkranz, Stephan, Preston, Ioana R., Rahaghi, Franck, Sood, Namita, Busse, Dennis, Meier, Christian and Humbert, Marc (2020). Efficacy and safety of riociguat in combination therapy for patients with pulmonary arterial hypertension (PATENT studies). Pulm. Circ., 10 (3). THOUSAND OAKS: SAGE PUBLICATIONS INC. ISSN 2045-8940

Full text not available from this repository.

Abstract

Many patients with pulmonary arterial hypertension do not achieve treatment goals with monotherapy, and therefore combination therapy is becoming the standard of care. The soluble guanylate cyclase stimulator riociguat is licensed for the treatment of pulmonary arterial hypertension; here we present findings from patients who were receiving combined riociguat plus endothelin receptor antagonists or non-intravenous prostanoids in the randomized, placebo-controlled PATENT-1 study and its open-label extension (PATENT-2). Moreover, we include new data from patients receiving early sequential combination therapy (three to six months of endothelin receptor antagonist treatment) or long-term background endothelin receptor antagonist therapy (>6 months). Patients were randomized to riociguat 2.5 mg-maximum (N = 131 pretreated patients) and placebo (N = 60 pretreated patients). Riociguat improved 6-min walking distance (PATENT-1 primary endpoint), functional capacity, and hemodynamics after 12 weeks in pretreated patients. The placebo-corrected changes in 6-min walking distance were +24 m in endothelin receptor antagonist-pretreated patients and +106 m in the small group of prostanoid-pretreated patients. In the early sequential combination and long-term background endothelin receptor antagonist groups, the placebo-corrected changes in 6-min walking distance were +65 m (95% CI: 17 to 113 m) and +13 m (95% CI: -8 to 33 m), respectively. In conclusion, these data suggest that early sequential combination of an endothelin receptor antagonist plus riociguat is a feasible treatment option. Both early sequential therapy and long-term background endothelin receptor antagonist plus riociguat were well tolerated in the PATENT studies.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Ghofrani, Hossein-ArdeschirUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Gruenig, EkkehardUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Jansa, PavelUNSPECIFIEDorcid.org/0000-0002-3711-7064UNSPECIFIED
Langleben, DavidUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Rosenkranz, StephanUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Preston, Ioana R.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Rahaghi, FranckUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Sood, NamitaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Busse, DennisUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Meier, ChristianUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Humbert, MarcUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-327622
DOI: 10.1177/2045894020942121
Journal or Publication Title: Pulm. Circ.
Volume: 10
Number: 3
Date: 2020
Publisher: SAGE PUBLICATIONS INC
Place of Publication: THOUSAND OAKS
ISSN: 2045-8940
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
LONG-TERM EXTENSION; SURVIVALMultiple languages
Cardiac & Cardiovascular Systems; Respiratory SystemMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/32762

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item